Press release
Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market Set to Reach $10.87 Billion by 2029 with 9.7% Yearly Growth
Nucleic Acid And Gene Therapies In Neuromuscular Disorders
The growing prevalence of genetic disorders is expected to drive the expansion of the nucleic acid and gene therapies market in neuromuscular disorders. Genetic disorders are diseases caused by abnormalities in an individual's DNA, either inherited or due to mutations. The rise in genetic disorders can be attributed to factors such as genetic mutations, environmental influences, lifestyle changes, and advancements in diagnostic capabilities. Nucleic acid and gene therapies address these disorders by correcting or replacing defective genes in neuromuscular conditions, restoring normal function. For instance, in May 2024, Cure SMA, a US-based non-profit organization, reported that approximately 9,000 to 9,500 people in the United States are living with Spinal Muscular Atrophy (SMA), with 37% having Type 2 SMA. The condition has an incidence rate of 1 in 15,000 births. As a result, the growing prevalence of genetic disorders is fueling the growth of the nucleic acid and gene therapies in neuromuscular disorders market.
Get Your Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market Report Here:
https://www.thebusinessresearchcompany.com/report/nucleic-acid-and-gene-therapies-in-neuromuscular-disorders-global-market-report
What growth opportunities are expected to drive the nucleic acid and gene therapies in neuromuscular disorders market's CAGR through 2034?
The nucleic acid and gene therapies for neuromuscular disorders market has seen strong growth, increasing from $6.84 billion in 2024 to $7.52 billion in 2025 at a CAGR of 9.9%. Growth has been driven by an increase in regulatory approvals, rising demand for nucleic acid and gene therapies, the need for more precise treatments, and an increasing number of gene therapy-based discoveries.
The nucleic acid and gene therapies in neuromuscular disorders market is poised for strong growth, reaching $10.87 billion by 2029, with a CAGR of 9.7%. Growth is driven by a rising prevalence of genetic disorders, increasing R&D investments, growing demand for precision medicine, higher approval rates for gene therapy products, and an increasing burden of chronic conditions. Emerging trends include advancements in patient care, high-performance chromatography, innovative treatment solutions, gene editing technologies, and improved nucleic acid extraction technologies.
Get Your Free Sample Now - Explore Exclusive Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=21233&type=smp
What are the emerging trends shaping the future of the nucleic acid and gene therapies in neuromuscular disorders market?
In the nucleic acid and gene therapies for neuromuscular disorders market, companies are focusing on gene therapy to address the genetic causes of neuromuscular conditions. For example, in June 2023, Sarepta Therapeutics Inc., a US-based biotechnology company, received FDA approval for Elevidys, the first gene therapy for Duchenne Muscular Dystrophy (DMD) in ambulatory pediatric patients aged 4 to 5 years. This therapy delivers a gene coding for a micro-dystrophin protein, which is essential for muscle function. The therapy offers a potential cure by addressing the underlying genetic defect, simplifying the treatment process with a single intravenous infusion, potentially halting or reversing disease progression in DMD patients.
Which growth-oriented segments of the nucleic acid and gene therapies in neuromuscular disorders market are leading the industry's development?
The nucleic acid and gene therapies in neuromuscular disorders market covered in this report is segmented -
1) By Disorder: Motor Neuron Diseases, Neuropathies, Neuromuscular Junction Disorders, Myopathies Including Muscular Dystrophies
2) By Therapy: Adeno-Associated Viruses Gene Therapy, Postnatal Gene Therapy, Spinal Muscular Atrophy
3) By Application: Hospitals, Specialty Clinics, Ambulatory Surgery Centers
Subsegments:
1) By Motor Neuron Diseases: Amyotrophic Lateral Sclerosis (ALS), Spinal Muscular Atrophy (SMA), Primary Lateral Sclerosis (PLS)
2) By Neuropathies: Charcot-Marie-Tooth Disease (CMT), Hereditary Sensory and Autonomic Neuropathy (HSAN), Peripheral Neuropathies
3) By Neuromuscular Junction Disorders: Myasthenia Gravis, Lambert-Eaton Myasthenic Syndrome (LEMS)
4) By Myopathies Including Muscular Dystrophies: Duchenne Muscular Dystrophy (DMD), Becker Muscular Dystrophy (BMD), Limb-Girdle Muscular Dystrophy (LGMD), Facioscapulohumeral Muscular Dystrophy (FSHD)
Unlock Exclusive Market Insights - Purchase Your Research Report Now!
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=21233
What regions are leading the charge in the nucleic acid and gene therapies in neuromuscular disorders market?
North America was the largest region in the nucleic acid and gene therapies in neuromuscular disorders market in 2024. The regions covered in the nucleic acid and gene therapies in neuromuscular disorders market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
What companies are at the forefront of innovation in the nucleic acid and gene therapies in neuromuscular disorders market?
Major companies operating in the nucleic acid and gene therapies in neuromuscular disorders market are Pfizer Inc., F. Hoffmann-La Roche Ltd., Bayer AG, Sanofi S.A, Novartis AG, Eli Lilly and Company, Astellas Pharma Inc, Biogen Inc, Vertex Pharmaceuticals Inc, BioMarin Pharmaceuticals Inc, Nippon Shinyaku Co Ltd, Sarepta Therapeutics Inc, Ionis Pharmaceuticals, Inc., Ultragenyx Pharmaceutical Inc, Amicus Therapeutics Inc, Arrowhead Pharmaceuticals Inc, Regenxbio Inc, UniQure N.V., Généthon S.A, Axovant Gene Therapies Inc.
Customize Your Report - Get Tailored Market Insights!
https://www.thebusinessresearchcompany.com/sample.aspx?id=21233&type=smp
What Is Covered In The Nucleic Acid And Gene Therapies In Neuromuscular Disorders Global Market Report?
•Market Size Forecast: Examine the nucleic acid and gene therapies in neuromuscular disorders market size across key regions, countries, product categories, and applications.
•Segmentation Insights: Identify and classify subsegments within the nucleic acid and gene therapies in neuromuscular disorders market for a structured understanding.
•Key Players Overview: Analyze major players in the nucleic acid and gene therapies in neuromuscular disorders market, including their market value, share, and competitive positioning.
•Growth Trends Exploration: Assess individual growth patterns and future opportunities in the nucleic acid and gene therapies in neuromuscular disorders market.
•Segment Contributions: Evaluate how different segments drive overall growth in the nucleic acid and gene therapies in neuromuscular disorders market.
•Growth Factors: Highlight key drivers and opportunities influencing the expansion of the nucleic acid and gene therapies in neuromuscular disorders market.
•Industry Challenges: Identify potential risks and obstacles affecting the nucleic acid and gene therapies in neuromuscular disorders market.
•Competitive Landscape: Review strategic developments in the nucleic acid and gene therapies in neuromuscular disorders market, including expansions, agreements, and new product launches.
Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.
Contact Us
Europe: +44 207 1930 708,
Asia: +91 88972 63534,
Americas: +1 315 623 0293 or
Email: mailto:info@tbrc.info
Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market Set to Reach $10.87 Billion by 2029 with 9.7% Yearly Growth here
News-ID: 3935128 • Views: …
More Releases from The Business Research Company
Segment Evaluation and Major Growth Areas in the Personalized Testing and Supple …
The personalized testing and supplements sector is gaining remarkable traction, driven by advancements in technology and a rising consumer focus on tailored health solutions. As more individuals seek customized wellness options, this market is set to experience substantial expansion in the coming years. Here's an in-depth look at its current valuation, key players, significant trends, and the main market segments shaping its future.
Market Valuation and Expansion Forecast for Personalized Testing…
Top Players and Market Competition in the Skin Microbiome Industry
The skin microbiome market is emerging as a significant area of interest due to growing awareness about the critical role of skin health and innovative skincare technologies. As research advances and consumer preferences shift towards more natural and science-backed products, this market is set to undergo substantial growth. Let's explore the current market size, key players, driving factors, and upcoming trends shaping the skin microbiome industry.
Projected Expansion in the Skin…
Key Strategic Developments and Emerging Changes Shaping the Upadacitinib Market …
The upadacitinib market is poised for significant expansion over the coming years, driven by advances in treatment options and increasing awareness of autoimmune diseases. This report delves into the market's current size, key drivers, major players, and the emerging trends shaping its future trajectory.
Steady Growth Expected in Upadacitinib Market Size Through 2029
The market for upadacitinib is projected to reach $2.54 billion by 2029, growing at a robust compound annual…
Analysis of Key Market Segments Driving the Alzheimer's Disease Diagnostic Marke …
The Alzheimer's disease diagnostic sector is rapidly evolving as advancements in technology and healthcare infrastructure open new possibilities for early detection and personalized treatment. With rising awareness and innovative approaches, this market is poised for significant growth in the coming years. Let's explore the current market size, key drivers, leading companies, and emerging trends that are shaping this critical healthcare field.
Projected Market Size and Growth Trends in Alzheimer's Disease Diagnostics…
More Releases for Gene
DNA and Gene Cloning Services Market Expands with Growing Focus on Complex Gene …
InsightAce Analytic Pvt. Ltd. has announced the publication of a market research report titled "Global DNA and Gene Cloning Services Market by Type of Service Offered (Custom Cloning, Sub-cloning, Gene Synthesis, and Others), Type of Gene (Complex Gene, Standard Gene, and Others), End-User Industry (Pharmaceutical, Academic and R&D, and Biotechnology Companies, and Others)- Market Outlook and Industry Analysis 2034"
The DNA and Gene Cloning Services Market Size is valued…
Evolving Market Trends In The CRISPR Gene Editing Industry: Innovative Gene Ther …
The CRISPR Gene Editing Market Report by The Business Research Company delivers a detailed market assessment, covering size projections from 2025 to 2034. This report explores crucial market trends, major drivers and market segmentation by [key segment categories].
What Is the Expected CRISPR Gene Editing Market Size During the Forecast Period?
The CRISPR gene editing market has grown exponentially in recent years. It will grow from $2.26 billion in 2024 to $2.88…
Cell and Gene Therapy Market Global Analysis By Type (Cell Therapy, Gene Therapy …
Gene and cell therapy uses genes and cells for the treatment of genetic diseases. Genetic diseases are caused by mutations, or errors in genes which can be passed down from one generation to another. Gene therapy aims to treat diseases by using genetic material, or DNA, to manipulate a patient's cells by replacing, changing or introducing genome into cells- either internally or externally. Cell therapy aims to treat diseases by…
Competitive and Opportunities Analysis of Gene Therapy Market of Gene Therapy Ma …
Global Gene Therapy Market accounted for US$ 2.05 billion in 2020 and is estimated to be US$ 12.29 billion by 2030 and is anticipated to register a CAGR of 19.8%. Gene therapy means fixing a working gene to an individual who features a damaged gene. The European Commission has approved this method for one particular treatment. The treatment by the merchandise Glybera uses an epidemic to infect muscle cells with…
Genetic Testing Market Size by Growth Opportunities, Top Key Players: GeneDx, In …
Genetic Testing Market Report provides an in-depth analysis of the overall market, The ripple effect of Coronavirus-Covid19 on the market needs to become part of strategy discussions to emerge strong. The report focuses on major key players, production details, their application, countries and also analyzes the global and key regions market potential and advantage, opportunity, and challenge, restraints, and risks.
The Top players Covered in report are GeneDx, Invitae, Pathway Genomics,…
Gene Synthesis Market by Top Manufacturers - Gene script, Gene Art (Thermofische …
The "Gene Synthesis Market" report Added by "Big Market Research", enumerates information about the industry in terms of market share, market size, revenue forecasts, and regional outlook. The report further illustrates competitive insights of key players in the business vertical followed by an overview of their diverse portfolios and growth strategies.
In the Gene Synthesis Market 2018 research report professionals describe the different facets of the industry with a specific goal…
